Company Overview
Olema Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to the discovery, development, and commercialization of novel therapies specifically targeting women's cancers. The company functions within the broader Healthcare sector, where its specific focus places it in the Biotechnology industry, a domain characterized by high innovation risks and significant reliance on research and development pipelines to generate future value. As of the latest reporting period, the company maintains a market capitalization of $1.24B and employs a workforce of 131 individuals to advance its proprietary product candidates. The valuation of $1.24B indicates that the market assigns a substantial value to Olema's intellectual property and pipeline assets, despite the absence of reported annual revenue figures, which is typical for clinical-stage entities that prioritize product development over current commercial sales.
Financial Health
The company reports a Net Income (TTM) of $-162,451,008 and an EBITDA of $-168,208,000, while the Revenue (TTM) figure is listed as N/A, reflecting the pre-revenue or negligible revenue status common in the biotechnology sector. The significant gap between the reported Net Income and EBITDA, alongside the lack of revenue, highlights an operational cost structure where expenses heavily outweigh any current income, resulting in a negative profit environment typical of companies in the discovery and development phases. Free Cash Flow stands at $-82,896,248, indicating that the company is consuming cash reserves to fund its operations and clinical trials, which limits immediate financial flexibility but is a necessary expenditure for advancing its lead product candidate, palazestrant. All three reported margins—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, which signifies that the company has not yet achieved profitability or that revenue figures are insufficient to calculate meaningful margins in the traditional sense. On the liability side, the company holds $505.44M in cash against $4.19M in debt, resulting in a Debt to Equity ratio of 0.88, suggesting a balance sheet that is largely funded by equity and cash rather than significant debt obligations. The Current Ratio is exceptionally high at 9.95, indicating a robust short-term liquidity position where current assets vastly exceed current liabilities, providing ample coverage for immediate obligations. However, the Return on Equity is -36.6% and the Return on Assets is -21.4%, revealing that management is currently generating negative returns on the capital invested, a metric expected during the heavy investment phase of clinical-stage biotechnology but one that signals a lack of profitable operations to date.
Valuation Assessment
The Trailing P/E Ratio (TTM) is N/A due to the lack of earnings, while the Forward P/E is -5.70, a negative figure that implies the market is valuing the company based on future expectations rather than current profitability, and the difference between these metrics underscores the speculative nature of investing in a loss-making entity. The Price to Book ratio is 2.42, suggesting that the market values the company at a premium of roughly 2.4 times its net asset value, which may reflect confidence in the future commercial potential of its pipeline despite current losses. Alternative valuation metrics such as the Price to Sales ratio, which is N/A, and the EV/EBITDA of -4.32, further illustrate that traditional earnings-based valuation models are not applicable, forcing reliance on asset-based or pipeline-specific valuations. The stock has exhibited significant volatility over the past year, trading between a 52-Week High of $36.26 and a 52-Week Low of $2.86, placing the current price in a wide range relative to the historical extremes. The Beta of 2.02 indicates that the stock's price volatility is more than double that of the broader market, exposing holders to substantial fluctuations in response to market movements or sector-specific news.
Growth & Income
Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, which prevents a direct comparison of growth rates and implies that the company is not yet in a stage where historical year-over-year expansion metrics are meaningful for analysis. Consequently, the concept of earnings growing faster or slower than revenue is inapplicable at this stage of the company's lifecycle, as the focus remains entirely on achieving product milestones rather than scaling commercial growth. Regarding income distribution, the Dividend Yield is N/A and the Payout Ratio is 0.0%, confirming that Olema Pharmaceuticals does not distribute dividends to shareholders. This absence of dividend payments aligns with the company's strategy of reinvesting all available capital, including its $505.44M cash reserve, directly back into research, development, and clinical trials to accelerate the path to market. The overall growth and income profile is defined by a complete reliance on capital appreciation and future product commercialization, offering no current income yield to investors and requiring patience regarding growth metrics until revenue generation commences.